Glenmark Pharmaceuticals Limited ua faʻalauiloaina se tala faʻapipiʻi tuʻufaʻatasiga (FDC) o se faʻaoga lautele DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, ma Pioglitazone. E na'o le pau lea o le DPP4 ma le Glitazone tu'ufa'atasiga o lo'o avanoa i Initia mo tagata matutua e le pulea le ma'isuka ituaiga 2. Ua faalauiloa e Glenmark lenei FDC i lalo ole igoa ole igoa ole Zita Plus Pio, lea e iai Teneligliptin (20 mg) + Pioglitazone (15 mg), e ave faatasi i le aso.

I le faʻamatalaga i le atinaʻe, na fai mai ai Alok Malik, Sui Peresetene Vaega & Ulu, Initia Formulations - Glenmark Pharmaceuticals, "O le maʻisuka o se vaega autu o le taulaiga mo Glenmark; o se paionia i le tuʻuina atu o avanoa i togafitiga sili ona lata mai mo tagata maʻi suka i Initia. Matou te fiafia e faʻalauiloa lenei tala Zita Plus Pio, o le muamua o lona ituaiga i Initia; ofo atu se togafiti fa'alelalolagi ma taugofie mo tagata mama'i ma'i suka."

O Glenmark o le kamupani muamua lea i Initia e maketi le FDC fou o Teneligliptin + Pioglitazone, lea e faʻamaonia e le DCGI (Drug Controller General o Initia). Ole tu'ufa'atasiga tu'ufa'atasiga tu'ufa'atasi ole a aoga mo tagata mama'i e mana'omia togafitiga ile Teneliglitptin ma Pioglitazone (e pei o vaila'au tu'ufa'atasi) e fa'aleleia atili ai le fa'atonuina ole glycemic fa'aitiitia le Fa'asagaga o Inisalini.

O le ma'isuka ituaiga 2 e masani lava ona feagai ma fa'afitauli o le fa'aletonu o le β cell ma le fa'ainisinia. Glenmark's FDC o Teneligliptin + Pioglitazone o loʻo i ai le aoga e foia ai nei pathophysiologies sili ona taua e lua lea e sili atu ai le aoga o le FDC i le puleaina o le maʻisuka ituaiga 2 le pulea. O le tuʻufaʻatasiga o Teneligliptin + Pioglitazone o le a maua ai se faiga faʻapitoa lea e mafai ai e Teneligliptin ona faʻaleleia atili le lagona o le β, ma o le Pioglitazone o le a faʻaitiitia lelei ai le faʻamalosia o le inisalini.

Ole sao ole Glenmark ile togafitiga ole ma'i suka

I le 2015, na faʻafouina ai e Glenmark le maketi o le maʻisuka e ala i le faʻalauiloaina o le DPP4 inhibitor - Teneligliptin i Initia, sosoo ai ma le FDC o Teneligliptin + Metformin. O Glenmark e iai sona talatuu malosi o le sili atu ma le fasefulu tausaga o le alualu i luma ma mea fou. I le faʻaauau i lona taimi muamua i Initia talatuu, ua faʻalauiloa FDC o Teneligliptin + Remogliflozin i le 2021.

Ua lauiloa Initia o le laumua o le ma'i suka i le lalolagi. E tusa ai ma le International Diabetes Federation (IDF), o le faʻateleina o le maʻisuka i Initia e tusa ma le 74 miliona tagata matutua, lea e faʻamoemoe e faʻateleina i le 125 miliona (toetoe lava 70% faʻateleina) i le 2045[i]. Mai nei mea, 77% o tagata mama'i e maua i le ma'isuka le pulea.

OA MEA E AVEA MAI LENEI TUSI:

Glenmark is the first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which is approved by the DCGI (Drug Controller General of India).
According to the International Diabetes Federation (IDF), the prevalence of diabetes in India is around 74 million adults, which is expected to increase to 125 million (nearly 70% increase) by 2045[i].
Glenmark’s FDC of Teneligliptin + Pioglitazone has the efficacy to tackle these two most important pathophysiologies which makes the FDC more effective in managing uncontrolled Type 2 diabetes.